New pill tested for aggressive breast cancer
NCT ID NCT03709446
Summary
This early-stage trial tested a daily pill called leflunomide in women with metastatic triple negative breast cancer (TNBC), a hard-to-treat form of the disease. The study first aimed to find a safe dose and then to see if the drug could help control the cancer. It involved 17 women whose cancer had progressed despite prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Mt Sinai Chelesa
New York, New York, 10011, United States
-
Mt Sinai West
New York, New York, 10019, United States
Conditions
Explore the condition pages connected to this study.